文章：

接受移植且至少接受过一线治疗的多发性骨髓瘤患者疾病进展的经济负担

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

原文发布日期：2021-02-16

DOI: 10.1038/s41408-021-00431-5

类型: Article

开放获取: 是

英文摘要：

Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney disease, or death within 12 months of LOT initiation. Annual HRU and costs in the first three LOTs (L1–L3) were compared for patients with versus without disease progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in L1–L3 were $18,359, $87,055, and $71,917, respectively, among LOTs initiated between 2006 and 2018. In LOTs initiated between 2013 and 2018, the figures were $46,024, $100,329, and $101,942 in L1–L3, respectively. The economic burden of disease progression is substantial in this population of MM patients who underwent SCT and received systemic anti-myeloma therapy.
 

摘要翻译： 

本研究利用美国大型医疗索赔数据库，评估了疾病进展对多发性骨髓瘤（MM）患者医疗资源利用（HRU）及成本的影响。研究对象为在接受一线及以上治疗（LOT）后、于初次MM诊断一年内接受首次干细胞移植（SCT）的患者。疾病进展定义为在LOT启动后12个月内出现以下情况：进入下一线治疗、发生骨转移、高钙血症、软组织浆细胞瘤、骨骼相关事件、急性肾脏疾病或死亡。通过逆概率处理加权法调整基线特征组间差异后，比较了疾病进展与非进展患者在前三线治疗（L1-L3）中的年度HRU与医疗成本。结果显示，在所有治疗线中，疾病进展患者的年均住院次数和医疗成本均高于非进展患者。在2006年至2018年启动的治疗中，L1-L3进展患者相比非进展患者的年度总增量成本分别为18,359美元、87,055美元和71,917美元；而在2013年至2018年启动的治疗中，L1-L3的增量成本分别为46,024美元、100,329美元和101,942美元。结论表明，在接受SCT及全身性抗骨髓瘤治疗的MM患者群体中，疾病进展会导致显著的经济负担。

原文链接：

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US